Epic Bio Presents Compelling Preclinical Data Supporting Clinical Initiation of EPI-321 for FSHD
June 16, 2023 06:16 ET
|
Epic Bio
- NHP studies demonstrate EPI-321’s favorable safety and pharmacokinetic profile - - IND and CTA applications planned for 2023 - SOUTH SAN FRANCISCO, Calif., June 16, 2023 (GLOBE NEWSWIRE) --...
Epic Bio to Present Preclinical Data at American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting
May 04, 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Epic BIO, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
SOLVE FSHD Invests in Epic Bio to Advance Potentially Curative Therapy
April 18, 2023 09:00 ET
|
Epic Bio
SOUTH SAN FRANCISCO, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today...
SOLVE FSHD Announces Appointment of Executive Director Dr. Eva Chin and Venture-Philanthropic Funding Structure
May 11, 2022 08:00 ET
|
Solve FSHD
VANCOUVER, British Columbia, May 11, 2022 (GLOBE NEWSWIRE) -- Following SOLVE FSHD’s recent acclaimed launch, the organization is pleased to formally announce the appointment of Dr. Eva Chin as the...
From apparel to clinical trials: Lululemon Founder Commits $100 Million to Find Cure for FSHD
March 08, 2022 14:30 ET
|
Solve FSHD
VANCOUVER, British Columbia, March 08, 2022 (GLOBE NEWSWIRE) -- The world’s most successful entrepreneurs are often willing to share how lessons learned and resilience have shaped their business...
Bionano Genomics’ Saphyr® System Used for Highly Accurate Detection of the Genetic Disorder FSHD as an Alternative to Southern Blot
February 06, 2019 08:00 ET
|
Bionano Genomics
SAN DIEGO, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and...
UPDATE – GrandOmics Biosciences Offers Genetic Test Using the Saphyr System for Molecular Diagnosis of Facioscapulohumeral Muscular Dystrophy (FSHD) in China
October 19, 2018 20:51 ET
|
Bionano Genomics; GrandOmics Biosciences
SAN DIEGO, Oct. 19, 2018 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and...
aTyr Pharma to Present Final Data for Resolaris Phase 1b/2 Trial in Patients with Early-Onset Facioscapulohumeral Muscular Dystrophy at the 22nd International Annual Congress of the World Muscle Society
September 27, 2017 08:00 ET
|
aTyr Pharma Inc.
SAN DIEGO, Sept. 27, 2017 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of immunology-based therapeutics, harnessing new...
aTyr Pharma Announces Second Quarter 2017 Operating Results and Provides an Update on Innovative Immunology Pipeline
August 14, 2017 16:05 ET
|
aTyr Pharma Inc.
– Resolaris Demonstrated Favorable Safety Profile in Rare Muscular Dystrophy Patients in Extension Studies –– iMod.Fc Program for Interstitial Lung Disease (ILD) on Track to Commence Phase 1 Clinical...
aTyr Pharma Presents Analyses of Resolaris Phase 1b/2 Trial in Patients with Limb Girdle Muscular Dystrophy 2B and Facioscapulohumeral Muscular Dystrophy at the American Academy of Neurology 69th Annual Meeting
April 24, 2017 08:00 ET
|
aTyr Pharma Inc.
- Resolaris Demonstrated Favorable Safety Profile and Promising Signals of Clinical Activity - - Resolaris has FDA Fast Track and Orphan Drug Designation for Limb Girdle Muscular Dystrophy 2B...